Analysts on Wall Street project that Bausch + Lomb (BLCO) will announce quarterly earnings of $0.17 per share in its forthcoming report, representing a decline of 26.1% year over year. Revenues are projected to reach $1.09 billion, increasing 9.6% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 18.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Bausch + Lomb (BLCO) . This company, which is in the Zacks Medical Services industry, shows potential for another earnings beat.When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 17.36%, on average, in the last two quarters.For t ...

The market expects Bausch + Lomb (BLCO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 21, 2024, might help the stock move higher if these key number ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start ...

Financial Data and Key Metrics Changes - Total company revenue for Q3 2023 was $1.007 billion, reflecting an 8% increase on a constant currency basis and a 7% increase on a reported basis compared to the prior year [12][11][27] - Adjusted gross margin for the quarter was 61.3%, up 80 basis points compared to Q3 2022 [24] - Adjusted EBITDA for Q3 was $187 million, negatively impacted by currency headwinds of approximately $14 million and Lynchburg-related disruptions of $7 million [54][26] Business Line Data and Key Metrics Changes - Vision Care revenue was $648 million, increasing by 11% on a constant currency basis, driven by growth in both consumer and contact lens portfolios [15] - Revenue from the Pharma segment was $174 million, representing constant currency growth of 1%, with VYZULTA growing by 54% [22][40] - The lens care portfolio grew by 8% on a constant currency basis, while the implantables segment declined by 2% [17][19] Market Data and Key Metrics Changes - The consumer business grew by 14% on a constant currency basis, led by LUMIFY, Eye Vitamins, and Artelac franchises [45] - The China business was down 1% on a constant currency basis, but year-to-date constant currency growth in China has been 6% [44] - Daily SiHy lenses reported a 79% revenue growth in the quarter [47] Company Strategy and Development Direction - The company is focused on addressing supply chain challenges and has made significant investments in improving its distribution facilities [10][62] - The launch of MIEBO and the acquisition of XIIDRA are seen as transformative for the Pharma business, with a strong emphasis on the Dry Eye Disease market [23][66] - The company expects 2024 to be one of the most active launch years in its history, with plans to strengthen its leadership in Dry Eye Disease [87][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the fundamentals of the eye care market remaining strong, with overall market growth expected to be mid-single digits [29] - The company anticipates currency headwinds to revenue of approximately $100 million in 2024, which will be monitored closely [31] - Management acknowledged the need for continued investment in product launches and the importance of maintaining high-quality supply [116][88] Other Important Information - The company raised its revenue guidance for 2023 to a range of $4.035 billion to $4.085 billion, reflecting a constant currency growth rate of approximately 9.5% to 10.5% [27] - The adjusted tax rate for the third quarter was 6%, in line with expectations for the full year [26] - The company is committed to investing in R&D, with approximately 8% of revenue allocated to this area [25] Q&A Session Summary Question: What is the outlook for XIIDRA and MIEBO sales next year? - Management indicated that XIIDRA is expected to stabilize and potentially achieve mid-single-digit growth, while MIEBO is showing promising early trends [78][76] Question: How is the company addressing supply chain issues? - Management emphasized a practical approach to supply chain improvements, with ongoing investments and strategic sourcing to enhance product availability [62][90] Question: What is the impact of the FDA warning on eye drops? - While the company was not directly affected, management noted that it underscores the importance of quality control and may create some market opportunities [116]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other ...

Financial Data and Key Metrics Changes - Total company revenue for Q2 2023 was $1.035 billion, reflecting a growth of 12% on a constant currency basis and 10% on a reported basis compared to the prior year [18][36] - Adjusted EBITDA for the quarter was $179 million, impacted by currency headwinds of approximately $25 million [64][70] - Adjusted gross margin for the quarter was 59.7%, flat compared to Q2 2022 [64] Business Line Data and Key Metrics Changes - Vision Care revenue was $646 million, increasing by 12% on a constant currency basis, driven by growth in both consumer and lens portfolios [24] - Surgical segment revenue was $195 million, an increase of 7% on a constant currency basis, with consumables growing by 11% [27] - Pharma segment revenues were $194 million, representing constant currency growth of 16%, with strong performance across all portfolios [28] Market Data and Key Metrics Changes - The China business grew 24% on a constant currency basis, contributing approximately 200 basis points to the overall second quarter growth [29] - The U.S. lens portfolio was negatively impacted by disruptions related to a new warehouse management system, particularly affecting the Ultra lens family [60] Company Strategy and Development Direction - The company is focused on improving supply chain efficiency and product delivery, with a roadmap to accelerate growth and enhance capabilities [15][80] - Investments in R&D are expected to be approximately 8% of revenue, with a commitment to support product launches and innovation [71] - The company aims to be a comprehensive eye care provider, not solely focused on pharmaceuticals, with a balanced approach across all business segments [44][135] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing supply challenges but expressed confidence in resolving these issues over time [40][141] - The company raised its revenue guidance for 2023 to a range of $3.95 billion to $4 billion, reflecting a constant currency growth rate of approximately 6.5% to 7.5% [67][68] - Management is optimistic about the upcoming product launches, particularly MIEBO, which is expected to be a significant contributor to growth [45][151] Other Important Information - The company announced the strategic acquisition of Blink to expand its OTC eye drop portfolio, although it is not expected to have a meaningful impact on 2023 financial results [59][122] - The XIIDRA transaction is expected to close by the end of 2023, subject to regulatory approvals [41] Q&A Session Summary Question: What is the quantifiable impact of supply challenges and the timing for resolution? - Management indicated that the supply chain issues have led to a quantifiable impact of approximately 600 basis points on the lens business growth, which would have been around 10% without these challenges [55][141] Question: How is the company addressing the supply chain issues? - The company is working to validate second vendors and has been engaging in spot buying to secure necessary components, although this has led to higher costs and margin pressure [54][141] Question: What are the expectations for the MIEBO launch? - The MIEBO launch is anticipated to be significant, with management expressing optimism about its market potential and the differentiated treatment it offers for dry eye disease [45][119] Question: How should investors think about growth in volumes versus pricing? - Management noted that the majority of growth in Q2 was driven by volume rather than price, indicating a focus on sustainable growth through volume increases [137]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other juri ...

Bausch + Lomb Corporation (NYSE:BLCO) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Allison Ryan - ED, IR Brent Saunders - CEO and Chairman Sam Eldessouky - EVP and CFO Conference Call Participants Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Joanne Wuensch - Citigroup Larry Biegelsen - Wells Fargo Cecilia Furlong - Morgan Stanley Craig Bijou - Bank of America Merrill Lynch Operator Good morning, and welcome to the Bausch + Lomb's First Quarter 2023 Earnings Call. All ...

All allocations and estimates in these Condensed Consolidated Financial Statements are based on assumptions that management believes are reasonable. On an ongoing basis, management reviews its allocations and estimates to ensure that these allocations and estimates appropriately reflect changes in the Company's business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company's bu ...